Suppr超能文献

癌症治疗的预处理:血液学/肿瘤学医疗服务提供者入门指南。

Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider.

作者信息

Clemmons Amber, Gandhi Arpita, Clarke Andrea, Jimenez Sarah, Le Thuy, Ajebo Germame

机构信息

University of Georgia College of Pharmacy, Augusta, Georgia.

Augusta University Medical Center, Augusta, Georgia.

出版信息

J Adv Pract Oncol. 2021 Nov;12(8):810-832. doi: 10.6004/jadpro.2021.12.8.4. Epub 2021 Nov 1.

Abstract

Chemotherapeutic agents and radiation therapy are associated with numerous potential adverse events (AEs). Many of these common AEs, namely chemotherapy- or radiation-induced nausea and vomiting, hypersensitivity reactions, and edema, can lead to deleterious outcomes (such as treatment nonadherence or cessation, or poor clinical outcomes) if not prevented appropriately. The occurrence and severity of these AEs can be prevented with the correct prescribing of prophylactic medications, often called "premedications." The advanced practitioner in hematology/oncology should have a good understanding of which chemotherapeutic agents are known to place patients at risk for these adverse events as well as be able to determine appropriate prophylactic medications to employ in the prevention of these adverse events. While several guidelines and literature exist regarding best practices for prophylaxis strategies, differences among guidelines and quality of data should be explored in order to accurately implement patient-specific recommendations. Herein, we review the existing literature for prophylaxis and summarize best practices.

摘要

化疗药物和放射治疗会引发众多潜在不良事件(AE)。这些常见不良事件中的许多,即化疗或放疗引起的恶心和呕吐、过敏反应以及水肿,如果未得到适当预防,可能会导致有害后果(如治疗依从性差或中断,或临床预后不佳)。通过正确开具预防性药物(通常称为“预处理药物”),可以预防这些不良事件的发生和严重程度。血液学/肿瘤学领域的高级从业者应充分了解哪些化疗药物会使患者面临这些不良事件的风险,并且能够确定用于预防这些不良事件的适当预防性药物。虽然存在一些关于预防策略最佳实践的指南和文献,但应探究指南之间的差异以及数据质量,以便准确实施针对特定患者的建议。在此,我们回顾现有预防文献并总结最佳实践。

相似文献

1
Premedications for Cancer Therapies: A Primer for the Hematology/Oncology Provider.
J Adv Pract Oncol. 2021 Nov;12(8):810-832. doi: 10.6004/jadpro.2021.12.8.4. Epub 2021 Nov 1.
3
Delayed Chemotherapy-Induced Nausea and Vomiting in the Hematology Population: A Review of the Literature.
Clin J Oncol Nurs. 2015 Aug;19(4):438-43. doi: 10.1188/15.CJON.438-443.
5
Antibiotic prophylaxis in veterinary cancer chemotherapy: A review and recommendations.
Vet Comp Oncol. 2018 Sep;16(3):301-310. doi: 10.1111/vco.12406. Epub 2018 Jun 12.
6
Antifungal prophylaxis in immunocompromised hosts.
Ann Pharmacother. 1993 Jan;27(1):53-60. doi: 10.1177/106002809302700114.
7
Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients.
Breast Cancer (Dove Med Press). 2011 Nov 14;3:151-60. doi: 10.2147/BCTT.S12955.
8
Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Oncologist. 2016 Apr;21(4):494-502. doi: 10.1634/theoncologist.2015-0301. Epub 2016 Mar 21.
9
International patterns of practice in the management of radiation therapy-induced nausea and vomiting.
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):e49-60. doi: 10.1016/j.ijrobp.2012.02.031. Epub 2012 Jun 15.
10
A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting.
SAGE Open Med. 2018 May 1;6:2050312118767234. doi: 10.1177/2050312118767234. eCollection 2018.

引用本文的文献

1
Adverse Reactions to Taxanes in Premedicated Cancer Patients: A Prospective Observational Study.
Cureus. 2025 Aug 7;17(8):e89590. doi: 10.7759/cureus.89590. eCollection 2025 Aug.
3
Intravenous Cetirizine Premedication to Mitigate Infusion-Related Reactions.
J Adv Pract Oncol. 2024 Mar;15(2):125-135. doi: 10.6004/jadpro.2024.15.2.5. Epub 2024 Mar 1.
4
Evaluation of Antiemetic Consistency in Chemotherapy-Induced Nausea and Vomiting Among NHL Patients in Sana'a, Yemen.
Int J Gen Med. 2024 May 13;17:2077-2090. doi: 10.2147/IJGM.S458922. eCollection 2024.

本文引用的文献

1
Antiemetics: ASCO Guideline Update.
J Clin Oncol. 2020 Aug 20;38(24):2782-2797. doi: 10.1200/JCO.20.01296. Epub 2020 Jul 13.
2
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.
J Natl Compr Canc Netw. 2020 Jun;18(6):676-681. doi: 10.6004/jnccn.2019.7526.
3
Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol.
Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):526-532.e1. doi: 10.1016/j.clml.2020.02.014. Epub 2020 Mar 7.
6
A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage.
Leuk Lymphoma. 2019 Dec;60(12):2854-2868. doi: 10.1080/10428194.2019.1608530. Epub 2019 May 17.
9
The feasibility of dexamethasone omission in weekly paclitaxel treatment for breast cancer patients.
Support Care Cancer. 2019 Mar;27(3):927-931. doi: 10.1007/s00520-018-4381-0. Epub 2018 Aug 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验